How to buy CASI Pharmaceuticals (CASI) stock

CASI Pharmaceuticals, Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 144 staff and has a trailing 12-month revenue of around 0.00.

CASI Pharmaceuticals stock price (NASDAQ: CASI)

Use our graph to track the performance of CASI stocks over time.

CASI Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$1.60
52-week range	$1.26 - $3.90
50-day moving average	$1.52
200-day moving average	$2.15
Wall St. target price	$4.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.44

Buy CASI Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy CASI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of CASI Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CASI Pharmaceuticals price performance over time

Historical closes compared with the close of $1.6 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	3.90%
3 months (2021-04-28)	-17.10%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

CASI Pharmaceuticals financials

Revenue TTM	$17.5 million
Gross profit TTM	$5.6 million
Return on assets TTM	-17.81%
Return on equity TTM	-49.63%
Profit margin	0%
Book value	$0.72
Market capitalisation	$184.5 million

TTM: trailing 12 months

Shorting CASI Pharmaceuticals shares

There are currently 3.2 million CASI Pharmaceuticals shares held short by investors – that's known as CASI Pharmaceuticals's "short interest". This figure is 40.2% down from 5.4 million last month.

There are a few different ways that this level of interest in shorting CASI Pharmaceuticals shares can be evaluated.

CASI Pharmaceuticals's "short interest ratio" (SIR)

CASI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CASI Pharmaceuticals shares currently shorted divided by the average quantity of CASI Pharmaceuticals shares traded daily (recently around 1.2 million). CASI Pharmaceuticals's SIR currently stands at 2.69. In other words for every 100,000 CASI Pharmaceuticals shares traded daily on the market, roughly 2690 shares are currently held short.

However CASI Pharmaceuticals's short interest can also be evaluated against the total number of CASI Pharmaceuticals shares, or, against the total number of tradable CASI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CASI Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CASI Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0358% of the tradable shares (for every 100,000 tradable CASI Pharmaceuticals shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CASI Pharmaceuticals.

Find out more about how you can short CASI Pharmaceuticals stock.

CASI Pharmaceuticals share dividends

We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.

Have CASI Pharmaceuticals's shares ever split?

CASI Pharmaceuticals's shares were split on a 1:11 basis on 30 June 2010. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.

CASI Pharmaceuticals share price volatility

Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.26 up to $3.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.136. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).

CASI Pharmaceuticals overview

CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co.

Frequently asked questions

What percentage of CASI Pharmaceuticals is owned by insiders or institutions?
Currently 29.937% of CASI Pharmaceuticals shares are held by insiders and 38.443% by institutions. How many people work for CASI Pharmaceuticals?
Latest data suggests 144 work at CASI Pharmaceuticals. When does the fiscal year end for CASI Pharmaceuticals?
CASI Pharmaceuticals's fiscal year ends in December. Where is CASI Pharmaceuticals based?
CASI Pharmaceuticals's address is: 9620 Medical Center Drive, Rockville, MD, United States, 20850 What is CASI Pharmaceuticals's ISIN number?
CASI Pharmaceuticals's international securities identification number is: US14757U1097 What is CASI Pharmaceuticals's CUSIP number?
CASI Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14757U109